Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/110906
Title: | Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis |
Author: | Serrano-Oviedo, Leticia Giménez-Bachs, José Miguel Nam-Cha, Syong Hyun Cimas, Francisco J. García-Cano, Jesús Sánchez-Prieto, Ricardo Salinas-Sánchez, Antonio S. |
Keywords: | Proteïnes Biologia molecular Marcadors tumorals Càncer de ronyó Metàstasi Proteins Molecular biology Tumor markers Renal cancer Metastasis |
Issue Date: | 8-Nov-2016 |
Publisher: | Elsevier Inc. |
Abstract: | Objectives: To determine the expression status of several proteins related to VHL gene function and its relationship with common clinicopathological parameters. Material and methods: Observational, analytical, cross-sectional study with 50 patients diagnosed with clear cell renal cell carcinoma. The study analyzed VHL mutations and hypermethylation as well as protein expression of VHL, CA-IX, HIF-1alpha, VEGF, ERK1/2, and ERK5, relating them to clinical variables. A bivariate and multivariate descriptive logistical regression analysis was performed, using the presence of metastasis at diagnosis as dependent variable. Results: The study identified 13 (26%) VHL mutations related to nuclear grade (P = 0.036). VHL hypermethylation was found in 20% of cases. VHL expression was associated with the presence of mutations (P = 0.013), and the absence of expression was associated with nuclear grade and the presence of metastasis (P<0.05). HIF-1alpha was negative in only 5 cases. Vascular endothelial growth factor (VEGF) was positive in 31 of 47 cases and was associated with Fuhrman nuclear grade, presence of metastasis, and stage (P<0.05). ERK5 expression was increased in 58% of cases and associated with the presence of metastasis and more advanced stages (P<0.05). In the logistic regression analysis, the only variable remaining in the model was VEGF expression (P = 0.014). Conclusions: VEGF has prognostic value in clear cell renal cell carcinoma, and ERK5 may be a new prognostic marker in this type of tumor owing to its relationship with metastasis and more advanced stages. |
Note: | Versió postprint del document publicat a: https://doi.org/10.1016/j.urolonc.2016.10.010 |
It is part of: | Urologic Oncology-Seminars and Original Investigations, 2017, vol. 35, num. 3, p. 114.e15-114.e22 |
URI: | http://hdl.handle.net/2445/110906 |
Related resource: | https://doi.org/10.1016/j.urolonc.2016.10.010 |
ISSN: | 1078-1439 |
Appears in Collections: | Articles publicats en revistes (Ciències Fisiològiques) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
670347.pdf | 670.71 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License